NCT04010305View on ClinicalTrials.gov

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
AgitationSchizophrenia
Interventions
DRUG

Sublingual film containing BXCL501 (Dexmedetomidine)

Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

DRUG

Placebo film

Placebo film for BXCL501

Trial Locations (12)

20877

BioXcel Clinical Research Site, Gaithersburg

30331

BioXcel Clinical Research Site, Atlanta

33016

BioXcel Clinical Research Site, Miami Lakes

39232

BioXcel Clinical Research Site, Flowood

72211

BioXcel Clinical Research Site, Little Rock

75080

BioXcel Clinical Research Site, Richardson

78754

BioXcel Clinical Research Site, Austin

90703

BioXcel Clinical Research Site, Cerritos

90806

BioXcel Clinical Research Site, Long Beach

91945

BioXcel Clinical Research Site, Lemon Grove

92868

BioXcel Clinical Research Site, Orange

08009

BioXcel Clinical Research Site, Berlin

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

BioXcel Therapeutics Inc

INDUSTRY